HK Stock Market Move | CARSGEN-B(02171) rose nearly 14% in early trading, KJC-2219 initiated clinical trials, and it is expected that CT041 will submit an NDA for gastric cancer treatment in the first half of the year.

CARSGEN-B(02171) rose nearly 14% in the morning session, up 12.94% as of press time, at 11 Hong Kong dollars, with a turnover of 94.11 million Hong Kong dollars. On the news front, KJC Pharma recently announced that its independently developed universal CAR-T cell therapy candidate KJ-C2219 targeting CD19/CD20 has completed the first subject dosing in an investigator-initiated clinical trial (IIT). KJ-C2219, based on the THANK-uPlus platform, is planned for the treatment of hematological malignancies and autoimmune diseases, and is currently undergoing an investigator-initiated clinical trial in China for relapsed/refractory B-cell non-Hodgkin lymphoma (R/RB-NHL). Guoyuan International previously pointed out that KJC Pharma is an innovative R&D-driven biotechnology company focused on innovative CAR-T cell therapy, with leading universal CAR-T technology. They have made breakthroughs in treating solid tumors with CAR-T, and CT041 for gastric cancer is expected to submit an NDA in the first half of 2025. The company already has a listed product, Saikai Ze, promoted by Huadong Medicine, which is expected to ramp up production soon.